Nervgen Pharma Corp (NGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -1,221 | -31,575 | -12,492 | -9,437 | -2,750 |
| Depreciation Amortization | 10 | 40 | 30 | 20 | 10 |
| Accounts receivable | -9 | 239 | 52 | 230 | 57 |
| Other Working Capital | -1,342 | 471 | 617 | 831 | 248 |
| Other Operating Activity | -3,414 | 16,869 | 2,282 | 2,728 | -433 |
| Operating Cash Flow | $-5,977 | $-13,956 | $-9,511 | $-5,628 | $-2,868 |
| Cash Flows From Investing Activities | |||||
| Other Investing Activity | 6 | 72 | 55 | 37 | 18 |
| Investing Cash Flow | $6 | $72 | $55 | $37 | $18 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 2,069 | 17,719 | 5,650 | 4,831 | 1,226 |
| Other Financing Activity | -43 | -711 | -553 | -474 | -338 |
| Financing Cash Flow | $2,026 | $17,008 | $5,097 | $4,357 | $888 |
| Exchange Rate Effect | -72 | 312 | 73 | 82 | 16 |
| Beginning Cash Position | 16,087 | 12,358 | 12,535 | 12,484 | 12,025 |
| End Cash Position | 12,070 | 15,795 | 8,249 | 11,333 | 10,078 |
| Net Cash Flow | $-4,017 | $3,437 | $-4,285 | $-1,152 | $-1,947 |
| Free Cash Flow | |||||
| Operating Cash Flow | -5,977 | -13,956 | -9,511 | -5,628 | -2,868 |
| Free Cash Flow | -5,977 | -13,956 | -9,511 | -5,628 | -2,868 |